Stable compositions of famotidine and ibuprofen

Details Stable compositions of famotidine and ibuprofen Stable compositions of famotidine and ibuprofen

2008-11-26

2011-11-29

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C514S370000, C514S570000

Reexamination Certificate

active

08067033

ABSTRACT:
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

REFERENCES:
patent: 4283408 (1981-08-01), Hirata et al.
patent: 4757060 (1988-07-01), Lukacsko et al.
patent: 5037815 (1991-08-01), Lukacsko et al.
patent: 5120850 (1992-06-01), Bod et al.
patent: 5128477 (1992-07-01), Bod et al.
patent: 5204118 (1993-04-01), Goldman et al.
patent: 5364616 (1994-11-01), Singer et al.
patent: 5384130 (1995-01-01), Kamada
patent: 5417980 (1995-05-01), Goldman et al.
patent: 5466436 (1995-11-01), Stables
patent: 5496836 (1996-03-01), Di Rocco et al.
patent: 5505983 (1996-04-01), Kamada
patent: 5601843 (1997-02-01), Gimet et al.
patent: 5696165 (1997-12-01), Armitage et al.
patent: 5747068 (1998-05-01), Mendizabal
patent: 5854267 (1998-12-01), Berlin et al.
patent: 5976578 (1999-11-01), Beyerle et al.
patent: 6149943 (2000-11-01), McTeigue et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 6455518 (2002-09-01), Zenke et al.
patent: 6544556 (2003-04-01), Chen et al.
patent: 6569463 (2003-05-01), Patel et al.
patent: 6613354 (2003-09-01), Depui et al.
patent: 6660303 (2003-12-01), Staniforth
patent: 6552047 (2004-04-01), Garvey et al.
patent: 6923988 (2005-08-01), Patel et al.
patent: 6926907 (2005-08-01), Plachetka
patent: 6951657 (2005-10-01), Zuccarelli et al.
patent: 7169809 (2007-01-01), Berthelette et al.
patent: 2003/0069255 (2003-04-01), Plachetka et al.
patent: 2003/0178031 (2003-09-01), Du Pen et al.
patent: 2004/0235802 (2004-11-01), Gimona
patent: 2005/0020671 (2005-01-01), Fernandez Ibanez et al.
patent: 2005/0053655 (2005-03-01), Yang et al.
patent: 2005/0163847 (2005-07-01), Cheng et al.
patent: 2005/0196459 (2005-09-01), Castan et al.
patent: 2005/0249806 (2005-11-01), Proehl et al.
patent: 2005/0249811 (2005-11-01), Plachetka
patent: 2006/0078614 (2006-04-01), Venkatesh
patent: 2006/0127478 (2006-06-01), Zerbe et al.
patent: 2006/0177504 (2006-08-01), Sundharadas
patent: 2007/0003490 (2007-01-01), Nijhawan
patent: 2007/0043096 (2007-02-01), Tidmarsh et al.
patent: 2007/0043097 (2007-02-01), Tidmarsh et al.
patent: 2008/0020040 (2008-01-01), Tidmarsh et al.
patent: 2008/0021078 (2008-01-01), Tidmarsh et al.
patent: 2008/0063706 (2008-03-01), Tidmarsh et al.
patent: 0 320 550 (1989-06-01), None
patent: 0 321 613 (1989-06-01), None
patent: 2 105 193 (1983-03-01), None
patent: WO 91/16886 (1991-11-01), None
patent: WO 94/07541 (1994-04-01), None
patent: WO 02/22108 (2002-03-01), None
patent: WO 02/066002 (2002-08-01), None
patent: WO 02/098352 (2002-12-01), None
patent: WO 2004/064815 (2004-08-01), None
patent: WO 2007/012019 (2007-01-01), None
patent: WO 2007/012022 (2007-01-01), None
patent: WO 2008/011426 (2008-01-01), None
patent: WO 2008/027963 (2008-03-01), None
patent: WO 2010/009432 (2010-01-01), None
Aly, A. M.; Kittaneh, R. H. Formulation and Evaluation of Famotidine and Ibuprofen Chewable Tablets. J. J. Appl. Sci., 2004, vol. 6, No. 2, pp. 1-7.
Notice of Allowance issued on Sep. 2, 2011 on U.S. Appl. No. 11/779,204.
Final Rejection issued on Aug. 12, 2011 on U.S. Appl. No. 11/489,275.
Advisory Action issued on Sep. 6, 2011 on U.S. Appl. No. 11/489,275.
Final rejection issued on Aug. 15, 2011 on U.S. Appl. No. 11/489,705.
Final rejection issued on Aug. 15, 2011 on U.S. Appl. No. 11/489,272.
Abraham et al., “National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs,” Gastroenterology 129:1171-1178 (2005).
Altman “Review of Ibuprofen for Osteoarthritis,” Am. J. Med. 10:18 (1984).
Aly et al., “Formulation and evaluation of famotidine and ibuprofen chewable tablets,” Jordan Journal of Applied Sciences-Natural Sciences 6(2):1-7 (2004).
American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs “Recommendations for Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs,” Arthritis & Rheumatism 59(3):1058-1073 (2008).
American Hospital Formulary Service. Drug Information 88, p. 1659-1664 (1988).
American Society of Health-System Pharmacists, AHFS Drug Information 2006. McEvoy, ed., pp. 2902-2908 (2006).
Analysis of HZ-CA-004 Study Data, prepared Nov. 2007.
Bell et al., “Time to maximum effect of lansoprazole on gastric pH in normal male volunteers,” Aliment. Pharmacal. Ther. 10(6):897-904 (1996).
Brady, W.M., M.D., et al., “Gastroesophageal reflux disease the long and the sort of therapeutic options”, Postgraduate Medicine online, 100(5) (1996).
Castell, D.O., “Rationale for high-dose H2-receptor blockade in the treatment of gastro-oesophageal reflux disease”, Ailment. Pharmacol. Therap., 1991,5 *Suppl. 1), 59-67.
Chambers et al., “A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients” P&T 27(7):462-467 (Jul. 2003).
Chremos et al, Clinical Pharmacology of Famotidine: a summary, (1987), J Clin Gastroenterolo, 9(Suppl 2):7-12.
Chremos et al, Pharmacodynamics of Famotidine in Humans, Am J Med, (1986), 81(Suppl 4B):24.
Cohen, “Dose Discrepancies Between the Physicians Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events”, Archive of Internal Medicine, Apr. 9, 2001, 161:957-964.
Copending U.S. Appl. No. 11/489,269, filed Jul. 18, 2006.
Copending U.S. Appl. No. 11/489,275, filed Jul. 18, 2006.
Copending U.S. Appl. No. 11/489,705, filed Jul. 18, 2006.
Copending U.S. Appl. No. 11/489,272, filed Jul. 18, 2006.
Davies “Clinical pharmacokinetics of ibuprofen. The first 30 years” Clin. Pharmacokinet. 34:101-154 (1998).
Davies et al, Ibuprofen: a review of its pharmacological properties, Drugs, (1971), 2:416-446.
De Klerk et al., Abstract of “Patient compliance in rheumatoid arthritis polymyalgia rheumatic, and gout” J. Rheumatol. 30(1):44-54 (Jan. 2003).
Dial et al., “Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy,” CMAJ 175(7):745-748 (Sep. 26, 2006).
Doherty et al., “Multiple Endocrine Neoplasias” Cancer: Principles and Practice of Oncology, 6th edition. J.B. Lippincott Co. pp. 1834-1839 (2001).
Drug Facts and Comparisions, 1997 Edition pp. 1387-1399, pp. 1933-1947.
DRUGS.COM, Famotidine Tablets, www.drugs.com/pro/famotindine, downloaded Jun. 7, 2007.
Duexis Label, 16 pages, Apr. 2011.
Echizen et al., “Clinical Pharmacokinetics of Famotidine,” Clin. Pharmacokinet. 21(3):178-194 (1991).
Edge et al, High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study, New Zealand Med J, (1990), 11:150-152.
Embase Abstract of Adel, et al., 2004, “Formulation and evaluation of famotidine and ibuprofen chewable tablets,” Jordan Journal of Applied Sciences—Natural Sciences, vol. 6, No. 2, pp. 1-7.
European Supplementary Search Report and Search Opinion issued in Patent Application 06800140.3; Mail Date: Nov. 13, 2009, Completion Date: Nov. 2, 2009.
European Supplementary Search Report and Search Opinion issued in Patent Application 07813027.5; Mail Date: Oct. 27, 2009, Completion Date: Oct. 15, 2009.
FDA Drug Bulletin, vol. 19, No. 1, Feb. 1989.
FDA Facsimile dated May 16, 2006 regarding IND 72,116 HZT-501 (Ibuprofen and Famotidine) EOP2 Meeting.
Federal Register, vol. 75, No. 169, Wednesday, Sep. 1, 2010.
Gabriel et al., “Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis,” Ann. Intern. Med. 115(10):787-796 (1991).
Garcia et al., “Gastrointestinal Prophylactic Therapy Among Patients with Arthritis Treated by Rheumatology Specialists”J. Rheumatol. (

Affiliated with

Also associated with

Rating

Stable compositions of famotidine and ibuprofen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable compositions of famotidine and ibuprofen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable compositions of famotidine and ibuprofen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4285410